Preparations are underway for a new hackathon focused on health and technology.
The first edition of MedHacks will be held Oct. 2-4 at the Bloomberg Center for Physics and Astronomy on the JHU Homewood Campus.
Following a $2 billion merger between DTZ and Cushman & Wakefield, David Gillece will head up the firm’s newly combined offices in Baltimore.
Gillece was regional managing principal with DTZ and before that held the same position with brokerage Cassidy Turley, which combined with DTZ last year.
Product development of any kind is challenging and full of unknowns, obstacles and pivots.
Medical device product development is certainly no different.
With med devices, when you throw in regulatory bodies, such as FDA and others internationally, it only complicates matters further.
University of Maryland Medicine (the University of Maryland Medical Center and the University of Maryland School of Medicine) and its Center for Metabolic Imaging and Image-Guided Therapeutics (CMIT) has begun to use MRI-guided focused ultrasound on a deep structure within the brain related to Parkinson’s disease – the globus pallidus.
In the first clinical trial of its kind, researchers from the Departments of Diagnostic Radiology & Nuclear Medicine, Neurosurgery and Neurology at CMIT are using magnetic resonance imaging (MRI) to guide ultrasound waves through the intact skin and skull to the globus pallidus. The University of Maryland is one of only two sites in the United States to offer this treatment to Parkinson’s patients.
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca.
The proceeds will be used to progress ADCT’s product portfolio, including ADCT-301 for lymphoma and leukemia now in Phase I and a collaboration to develop up to two ADCs for commercialisation with MedImmune, the global biologics research and development arm of AstraZeneca. ADCT’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with highly potent pyrrolobenzodiazepine (PBD)-based warheads. ADCT anticipates having seven drug candidates in human clinical trials in 2017.
D.C.-based startup incubator 1776, which filed with regulators last year to raise its first seed fund, announced Tuesday it has closed the fund at $12.5 million, half of what it had expected to raise.
1776 has backed 20 companies since launching the fund, co-investing with other groups including 500 Startups, Silicon Valley Angels and GovTech Fund. The fund typically invests an average of $100,000 in pre-Series A startups focused on highly regulated industries, such as health, education, energy and transportation.
University of Maryland, Baltimore County, and Johns Hopkins University are among 12 universities that will share a $20 million grant for groundbreaking nanotechnology research.
The institutions are all part of the Center for Sustainable Nanotechnology at the University of Wisconsin-Madison. The five-year, $20 million grant from the National Science Foundation will support the center research of how nanoparticles interact with live beings and the environment.
Synthetic Biologics, a microbiome-focused clinical-stage biotechnology company, is moving its offices to the Johns Hopkins University Montgomery County Campus. Synthetic Biologics previously had its corporate headquarters at the VisArts incubator space in downtown Rockville but is moving its staff of 15 to the JHU campus, with plans to add more staff members in the future. The company has its administrative and financial offices in Ann Arbor, Mich.
The company is developing drugs to protect the gut microbiome in an effort to maintain the natural balance of bacteria in the gastrointestinal tract, which is important to our overall health, said Kris Maly, the company’s vice president of corporate communications.
A lot of time, effort and money goes into the creation of new drugs. A new game Big Pharma, which came out Thursday, is giving users the opportunity to see for themselves by running a virtual pharmaceutical company.
Not unlike Big Pharma in real life, one of your biggest priorities is money. It’s up to you whether or not you want to sacrifice efficacy to make cheaper products and yield more profit.
A digital health fund to invest in Israeli digital health startups recently made its first investment — Intendu. The company provides a way for people with neurological problems stemming from traumatic brain injury to age-related cognitive decline to train the brain through a series of personalized exercises that involve body-controlled adaptive videogames. The goals are customized to each user.
Partners for digital health venture fund eHealth Ventures include Cleveland Clinic Innovations, which is providing resources to the company in exchange for equity, and one of Israel’s largest HMOs, Maccabi Healthcare, are also supporting the fund.